NASDAQ:ONTX - Onconova Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.5233 0.00 (0.00 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$0.5233
Today's Range$0.51 - $0.54
52-Week Range$0.33 - $2.83
Volume1.19 million shs
Average Volume1.53 million shs
Market Capitalization$41.52 million
P/E Ratio-0.20
Dividend YieldN/A
Beta0.44
Onconova Therapeutics logoOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONTX
CUSIPN/A
Phone267-759-3680

Debt

Debt-to-Equity RatioN/A
Current Ratio0.81
Quick Ratio0.81

Price-To-Earnings

Trailing P/E Ratio-0.20
Forward P/E Ratio-0.52
P/E GrowthN/A

Sales & Book Value

Annual Sales$790,000.00
Price / Sales51.41
Cash FlowN/A
Price / CashN/A
Book Value($1.01) per share
Price / Book-0.52

Profitability

EPS (Most Recent Fiscal Year)($2.68)
Net Income$-24,090,000.00
Net Margins-1,826.64%
Return on EquityN/A
Return on Assets-216.65%

Miscellaneous

Employees25
Outstanding Shares77,610,000

Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Shares of Onconova Therapeutics reverse split on the morning of Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics Inc (NASDAQ:ONTX) posted its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.05. The biopharmaceutical company earned $0.56 million during the quarter, compared to the consensus estimate of $0.48 million. View Onconova Therapeutics' Earnings History.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Onconova Therapeutics.

What price target have analysts set for ONTX?

3 brokerages have issued 12 month price targets for Onconova Therapeutics' shares. Their predictions range from $3.00 to $6.00. On average, they anticipate Onconova Therapeutics' stock price to reach $4.50 in the next twelve months. View Analyst Ratings for Onconova Therapeutics.

What are Wall Street analysts saying about Onconova Therapeutics stock?

Here are some recent quotes from research analysts about Onconova Therapeutics stock:
  • 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (5/19/2018)
  • 2. Maxim Group analysts commented, "Summary We discuss in more detail below the meaning of the Interim analysis and the path to approval, including timelines and costs. Can Onconova get there? There are hurdles (aren’t there for most microcap biotech companies?), but we believe they can eventually, based on the fundamental prospects of Rigosertib." (3/26/2018)
  • 3. HC Wainwright analysts commented, "Buy-rated Cytori Therapeutics, Inc. (CYTX, $0.70 PT) reported 4Q17 results AMC Thursday, 3/8/2018, and held a corresponding conference call at 5:30pm ET. CYTX posted a top line/ EPS/adj. EBITDA of $1.5M/($0.20)/($2.9)M versus our estimate of $2.0M/($0.10)/($3.3)M and consensus $2.6M/($0.10)/($1.7)M. The revenue miss was primarily due to lower Celution Systems sales in Japan as 4Q government contract revenue through BARDA for the R&D of medical countermeasures for thermal burns of $0.9M was just shy of our $1.0M estimate. BARDA revenues should continue to increase as CYTX gets ready to commence its pilot trial (for additional info, see Quick Note dated 6/1/17). Meanwhile, CYTX’s EPS would have been in line with our projection but the company recognized $4.0M in one-time non-cash expenses related to a beneficial conversion feature for convertible preferred stock. CYTX’s adj." (3/9/2018)

Are investors shorting Onconova Therapeutics?

Onconova Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totalling 852,160 shares, a drop of 43.2% from the April 30th total of 1,499,501 shares. Based on an average daily trading volume, of 1,305,010 shares, the short-interest ratio is currently 0.7 days. Approximately 1.2% of the company's stock are sold short. View Onconova Therapeutics' Current Options Chain.

Who are some of Onconova Therapeutics' key competitors?

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the folowing people:
  • Dr. Ramesh Kumar, Co-Founder, CEO, Pres & Director (Age 62)
  • Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 55)
  • Dr. Steven M. Fruchtman, Chief Medical Officer and Sr. VP of R&D (Age 67)
  • Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 74)
  • Mr. Mark Patrick Guerin, CFO & Principal Accounting Officer (Age 49)

Has Onconova Therapeutics been receiving favorable news coverage?

Media headlines about ONTX stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Onconova Therapeutics earned a news sentiment score of 0.24 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 44.67 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sabby Management LLC (1.97%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, E Premkumar Reddy, Henry S Bienen, Mark Patrick Guerin and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics.

Which institutional investors are selling Onconova Therapeutics stock?

ONTX stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Onconova Therapeutics.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $0.5233.

How big of a company is Onconova Therapeutics?

Onconova Therapeutics has a market capitalization of $41.52 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-24,090,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]


MarketBeat Community Rating for Onconova Therapeutics (ONTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  296
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.